Elevated plasma endoglin (CD105) predicts decreased response and survival in a metastatic breast cancer trial of hormone therapy
Authors:
- 30 December 2008
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 119 (3) , 767-771
Abstract
Background Endoglin (CD105) is a co-receptor for TGF-β, is expressed by human vascular endothelial cells, and plays a major role in angiogenesis. Materials and methods Pretreatment EDTA plasma from 224 metastatic breast cancer patients enrolled in a phase III 2nd-line hormone therapy trial and 50 control subjects were assayed for endoglin using an ELISA. Results The female control group (n = 50) plasma endoglin upper limit of normal was defined as the mean + 2 SD (8.7 ng/ml). The breast cancer patient plasma endoglin was 6.40 ± 2.23 ng/ml (range 3.00–19.79 ng/ml). Elevated plasma endoglin levels were detected in 26 of 224 patients (11.6%). Patients with elevated plasma endoglin had a reduced clinical benefit rate (CR + PR + Stable) (15 vs. 42%) (P = 0.01) to hormone therapy. TTP was shorter for patients with elevated plasma endoglin, but did not reach statistical significance (P = 0.2). Patients with elevated plasma endoglin had decreased overall survival (median 645 vs. 947 days) (P = 0.005). Conclusion Elevated pretreatment plasma endoglin levels predicted for decreased clinical benefit and a shorter overall survival in metastatic breast cancer patients treated with 2nd-line hormone therapy.Keywords
This publication has 22 references indexed in Scilit:
- Endoglin (CD105): A Marker of Tumor Vasculature and Potential Target for TherapyClinical Cancer Research, 2008
- Endoglin expression in metastatic breast cancer cells enhances their invasive phenotypeOncogene, 2008
- Endoglin Is Not Critical for Hematopoietic Stem Cell Engraftment and Reconstitution but Regulates Adult Erythroid DevelopmentStem Cells, 2007
- The relationship of the neo-angiogenic marker, endoglin, with response to neoadjuvant chemotherapy in breast cancerBritish Journal of Cancer, 2006
- CD105 Expression Is a Marker of High Metastatic Risk and Poor Outcome in Breast CarcinomasAmerican Journal of Clinical Pathology, 2003
- Defective Angiogenesis in Mice Lacking EndoglinScience, 1999
- Endoglin Is an Accessory Protein That Interacts with the Signaling Receptor Complex of Multiple Members of the Transforming Growth Factor-β SuperfamilyJournal of Biological Chemistry, 1999
- Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: Results of two randomized double blind controlled multiinstitutional trialsCancer, 1996
- Serum levels of the TGF-beta receptor are increased in atherosclerosisAtherosclerosis, 1996
- Identification of distinct epitopes of endoglin, an RGD-containing glycoprotein of endothelial cells, leukemic cells, and syncytiotrophoblastsInternational Immunology, 1992